Review
Copyright ©2010 Baishideng Publishing Group Co.
World J Clin Oncol. Feb 10, 2011; 2(2): 125-134
Published online Feb 10, 2011. doi: 10.5306/wjco.v2.i2.125
Figure 9
Figure 9 A pooled analysis of two randomized controlled trials (N•SAS-BC 01 trial and CUBC trial). Relapse-free survival (RFS) according to estrogen receptor (ER) + and age ≥ 50 years. [tegafur/uracil (UFT) vs chemotherapy (CMF), hazard ratio (HR) = 0.58, 95% CI: 0.34-1.01]. (Source: Figure 5 in reference 9).